Literature DB >> 17501957

Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection.

S Debarbieux1, G Duru, S Dalle, O Béatrix, B Balme, L Thomas.   

Abstract

BACKGROUND: Sentinel lymph node (SLN) positivity has been found to be strongly associated with a poor prognosis in melanoma.
OBJECTIVES: This large referral centre study was conducted: (i) to confirm the powerful prognostic value of SLN biopsy (SLNB); (ii) to correlate patient prognosis to the micromorphometric features of SLN metastasis in SLN-positive patients; and (iii) to correlate these micromorphometric features to the likelihood of positive completion lymph node dissection (CLND). PATIENTS AND METHODS: SLNB was performed in 455 cases of primary melanoma between January 1999 and December 2004; for patients with positive SLN, the following micromorphometric features were registered: size of the largest metastasis (two diameters), depth of metastasis, number of millimetric slices involved, maximum number of metastases on a single section, presence of intracapsular lymphatic invasion and extracapsular spread. Kaplan-Meier survival curves were compared with the log-rank test; multivariate analysis was performed using a Cox regression model. Dependence of CLND status on micromorphometric features of SLN was assessed by the chi(2) test and predictive values of the different features were evaluated by multivariate analysis using a logistic regression model.
RESULTS: A positive SLN was identified in 98 of our 455 cases. Survival was significantly shorter in SLN-positive patients than in SLN-negative patients. Extracapsular invasion was found to be an independent prognostic factor of disease-free survival; ulceration of the primary and the maximum diameter of the largest metastasis were identified as independent predictive factors of disease-specific survival. Age and the lowest diameter of the largest metastasis were identified as independent predictive criteria of positive CLND, whereas depth of metastasis was not. Positivity of CLND was not significantly associated with a worse prognosis.
CONCLUSIONS: Our study confirms the previously demonstrated strong prognostic value of SLNB. It also confirms the relationship between tumour burden in the SLN (evaluated by the maximum diameter of the largest metastasis) and clinical outcome. We point out a new micromorphometric feature of SLN, which seems to be predictive of CLND status: the lowest diameter of the largest metastasis.

Entities:  

Mesh:

Year:  2007        PMID: 17501957     DOI: 10.1111/j.1365-2133.2007.07937.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  11 in total

1.  Extracapsular Spread in Melanoma Lymphadenopathy: Prognostic Implications, Classification, and Management.

Authors:  Michelle Lo; Alyss Robinson; Ryckie Wade; Howard Peach; Donald Dewar; Martin Heaton; Marc Moncrieff
Journal:  Ann Surg Oncol       Date:  2020-09-17       Impact factor: 5.344

Review 2.  Importance of tumor load in the sentinel node in melanoma: clinical dilemmas.

Authors:  Alexander C J van Akkooi; Cornelis Verhoef; Alexander M M Eggermont
Journal:  Nat Rev Clin Oncol       Date:  2010-06-22       Impact factor: 66.675

Review 3.  Progression of cutaneous melanoma: implications for treatment.

Authors:  Stanley P L Leong; Martin C Mihm; George F Murphy; Dave S B Hoon; Mohammed Kashani-Sabet; Sanjiv S Agarwala; Jonathan S Zager; Axel Hauschild; Vernon K Sondak; Valerie Guild; John M Kirkwood
Journal:  Clin Exp Metastasis       Date:  2012-08-15       Impact factor: 5.150

Review 4.  Significance of sentinel lymph node biopsy in malignant melanoma: overview of international data.

Authors:  Yoichi Moroi
Journal:  Int J Clin Oncol       Date:  2009-12-05       Impact factor: 3.402

5.  Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma.

Authors:  Rajmohan Murali; Alistair J Cochran; Martin G Cook; Joseph D Hillman; Rooshdiya Z Karim; Marc Moncrieff; Hans Starz; John F Thompson; Richard A Scolyer
Journal:  Cancer       Date:  2009-11-01       Impact factor: 6.860

6.  Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China.

Authors:  Mengze Hao; Gang Zhao; Xiaoling Du; Yun Yang; Jilong Yang
Journal:  Tumour Biol       Date:  2016-02-04

Review 7.  Current management of melanoma patients with nodal metastases.

Authors:  Dale Han; Alexander C J van Akkooi; Richard J Straker; Adrienne B Shannon; Giorgos C Karakousis; Lin Wang; Kevin B Kim; Douglas Reintgen
Journal:  Clin Exp Metastasis       Date:  2021-05-07       Impact factor: 4.510

8.  Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literature.

Authors:  Giorgia L Garrett; Steven Y He; Nica Sabouni; Adil Daud; Sarah T Arron
Journal:  JAAD Case Rep       Date:  2015-11-24

9.  Sentinel lymph node biopsy in melanoma: our 8-year clinical experience in a single French institute (2002-2009).

Authors:  Caroline Biver-Dalle; Eve Puzenat; Marc Puyraveau; Delphine Delroeux; Hatem Boulahdour; Frances Sheppard; Fabien Pelletier; Philippe Humbert; François Aubin
Journal:  BMC Dermatol       Date:  2012-12-10

10.  Long-term survival analysis and clinical follow-up in acral lentiginous malignant melanoma undergoing sentinel lymph node biopsy in korean patients.

Authors:  Su-Young Jeon; Jin-Woo Hong; Suee Lee; Sung Yong Oh; Young-Seoub Hong; Ki-Ho Kim; Ki-Hoon Song
Journal:  Ann Dermatol       Date:  2014-04-30       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.